285
Views
61
CrossRef citations to date
0
Altmetric
Review

Nalfurafine hydrochloride to treat pruritus: a review

Pages 249-255 | Published online: 11 May 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Dylan E. Lee, Ashley K. Clark, Khiem A. Tran & Vivian Y. Shi. (2018) New and emerging targeted systemic therapies: a new era for atopic dermatitis. Journal of Dermatological Treatment 29:4, pages 364-374.
Read now
Manuel P. Pereira & Sonja Ständer. (2018) Therapy for pruritus in the elderly: a review of treatment developments. Expert Opinion on Pharmacotherapy 19:5, pages 443-450.
Read now
Shayan Shirazian, Olufemi Aina, Youngjun Park, Nawsheen Chowdhury, Kathleen Leger, Linle Hou, Nobuyuki Miyawaki & Vandana S Mathur. (2017) Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges. International Journal of Nephrology and Renovascular Disease 10, pages 11-26.
Read now
Tasuku Nakasone, Hirokazu Wakuda, Yumi Sugimoto & Chiaki Kamei. (2017) Effects of ICI204,448, naloxone methiodide and levocetirizine on the scratching behavior induced by a κ-opioid antagonist, nor-BNI, in ICR mice. Immunopharmacology and Immunotoxicology 39:5, pages 292-295.
Read now
Carolyn Stull, Michael J. Lavery & Gil Yosipovitch. (2016) Advances in therapeutic strategies for the treatment of pruritus. Expert Opinion on Pharmacotherapy 17:5, pages 671-687.
Read now

Articles from other publishers (56)

Caroline M. Kopruszinski, Moe Watanabe, Ashley L. Martinez, Luiz Henrique Moreira de Souza, David W. Dodick, Aubin Moutal, Volker Neugebauer, Frank Porreca & Edita Navratilova. (2023) Kappa opioid receptor agonists produce sexually dimorphic and prolactin-dependent hyperalgesic priming. Pain 164:6, pages e263-e273.
Crossref
Zahra Z. Farahbakhsh, Keaton Song, Hannah E. Branthwaite, Kirsty R. Erickson, Snigdha Mukerjee, Suzanne O. Nolan & Cody A. Siciliano. (2023) Systemic kappa opioid receptor antagonism accelerates reinforcement learning via augmentation of novelty processing in male mice. Neuropsychopharmacology 48:6, pages 857-868.
Crossref
Jae-Hoon Jung, In Hee Jang, Moon Young Yang, Sunhong Kim, Soo-Kyung Kim, William A. GoddardIIIIII & Yong-Chul Kim. (2023) Discovery and Binding Mechanism of Pyrazoloisoquinoline-Based Novel β-Arrestin Inverse Agonists of the Kappa-Opioid Receptor. Journal of Medicinal Chemistry 66:7, pages 5154-5170.
Crossref
Amal El Daibani, Joseph M. Paggi, Kuglae Kim, Yianni D. Laloudakis, Petr Popov, Sarah M. Bernhard, Brian E. Krumm, Reid H. J. Olsen, Jeffrey Diberto, F. Ivy Carroll, Vsevolod Katritch, Bernhard Wünsch, Ron O. Dror & Tao Che. (2023) Molecular mechanism of biased signaling at the kappa opioid receptor. Nature Communications 14:1.
Crossref
Federica Santino & Luca Gentilucci. (2023) Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects. Molecules 28:1, pages 346.
Crossref
Oluwatoyin I. Ameh, Udeme E. Ekrikpo, Aminu K. Bello & Ikechi G. Okpechi. 2023. Management of Kidney Diseases. Management of Kidney Diseases 363 382 .
Masahiro Yamaguchi, Kanako Miyano, Shigeto Hirayama, Yusuke Karasawa, Kaori Ohshima, Eiko Uezono, Akane Komatsu, Miki Nonaka, Hideaki Fujii, Keisuke Yamaguchi, Masako Iseki, Masakazu Hayashida & Yasuhito Uezono. (2022) Evaluation of the Intracellular Signaling Activities of κ-Opioid Receptor Agonists, Nalfurafine Analogs; Focusing on the Selectivity of G-Protein- and β-Arrestin-Mediated Pathways. Molecules 27:20, pages 7065.
Crossref
Adhyatm Bhandari & Rahul Mahajan. (2022) Skin Changes in Cirrhosis. Journal of Clinical and Experimental Hepatology 12:4, pages 1215-1224.
Crossref
Nesligül AYBEK & Fatma ÖZKAN TUNCAY. (2022) Effect of Pruritus on Sleep Quality in Individuals Undergoing Hemodialysis Effect of Pruritus on Sleep Quality. Clinical and Experimental Health Sciences 12:2, pages 541-547.
Crossref
Sally L. Huskinson, Donna M. Platt, C. Austin Zamarripa, Kristen Dunaway, Morgan Brasfield, Thomas E. Prisinzano, Bruce E. Blough & Kevin B. Freeman. (2022) The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys. Pharmacology Biochemistry and Behavior 217, pages 173394.
Crossref
Richard M. Van Rijn & Mariana Spetea. (2022) Opioids and Their Receptors: Present and Emerging Concepts in Opioid Drug Discovery II. Molecules 27:10, pages 3140.
Crossref
Chiara Sturaro, Davide Malfacini, Michela Argentieri, Francine M. Djeujo, Erika Marzola, Valentina Albanese, Chiara Ruzza, Remo Guerrini, Girolamo Calo’ & Paola Molinari. (2022) Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands. Frontiers in Pharmacology 13.
Crossref
Dorottya Ádám, József Arany, Kinga Fanni Tóth, Balázs István Tóth, Attila Gábor Szöllősi & Attila Oláh. (2022) Opioidergic Signaling—A Neglected, Yet Potentially Important Player in Atopic Dermatitis. International Journal of Molecular Sciences 23:8, pages 4140.
Crossref
Attila Gábor Szöllősi, Attila Oláh, Erika Lisztes, Zoltán Griger & Balázs István Tóth. (2022) Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk. Frontiers in Pharmacology 13.
Crossref
Esperanza Regueras, Luis Miguel Torres & Ignacio Velazquez. (2022) Nuevas estrategias y generaciones de analgésicos opioides: ¿qué se está investigando?. Multidisciplinary Pain Journal.
Crossref
Xin Wang, Xiaoli Gou, Xiaojuan Yu, Dongdong Bai, Bowei Tan, Pingfeng Cao, Meilin Qian, Xiaoxiao Zheng, Hairong Wang, Pingming Tang, Chen Zhang, Fei Ye & Jia Ni. (2021) Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch. Frontiers in Pharmacology 12.
Crossref
Hendrik Jonas, Daniele Aiello, Bastian Frehland, Kirstin Lehmkuhl, Dirk Schepmann, Jens Köhler, Patrizia Diana & Bernhard Wünsch. (2021) Synthesis and pharmacological evaluation of enantiomerically pure endo -configured KOR agonists with 2-azabicyclo[3.2.1]octane scaffold . Organic & Biomolecular Chemistry 19:38, pages 8384-8396.
Crossref
Eriko Kinugasa, Ken Igawa, Hisaki Shimada, Morihiro Kondo, Satoshi Funakoshi, Naoki Imada, Noritomo Itami, Naoki Fukazawa, Ryoko Takubo, Yuichi Kawata & Hiroyuki Murota. (2021) Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study. Clinical and Experimental Nephrology 25:8, pages 875-884.
Crossref
Franz J. Legat. (2021) Itch in Atopic Dermatitis – What Is New?. Frontiers in Medicine 8.
Crossref
Hurramhon Shokirova, Takenori Inomata, Tsuyoshi Saitoh, Jun Zhu, Kenta Fujio, Yuichi Okumura, Ai Yanagawa, Keiichi Fujimoto, Jaemyoung Sung, Atsuko Eguchi, Maria Miura, Ken Nagino, Kunihiko Hirosawa, Mizu Kuwahara, Yasutsugu Akasaki, Hiroshi Nagase & Akira Murakami. (2021) Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation. Scientific Reports 11:1.
Crossref
Shirin Kahremany, Lukas Hofmann, Marco Harari, Arie Gruzman & Guy Cohen. (2021) Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives. Pharmacological Reports 73:2, pages 443-453.
Crossref
Huiqun Wang, Danni Cao, James C Gillespie, Rolando E Mendez, Dana E Selley, Lee-Yuan Liu-Chen & Yan Zhang. (2021) Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators. Future Medicinal Chemistry 13:6, pages 551-573.
Crossref
Shane W. Kaski, Allison N. White, Joshua D. Gross & David P. Siderovski. (2020) Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review. Anesthesia & Analgesia 132:2, pages 406-419.
Crossref
C. Austin Zamarripa, Tilak R. Patel, B. Cole Williams, Tanya Pareek, Hayley M. Schrock, Thomas E. Prisinzano & Kevin B. Freeman. (2020) The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone’s conditioned rewarding effects in male rats. Behavioural Pharmacology 31:8, pages 792-797.
Crossref
Kathryn L. Reichard, Keionna A. Newton, Zeena M.G. Rivera, Paulo M. Sotero de Menezes, Selena S. Schattauer, Benjamin B. Land & Charles Chavkin. (2020) Regulation of Kappa Opioid Receptor Inactivation Depends on Sex and Cellular Site of Antagonist Action. Molecular Pharmacology 98:5, pages 548-558.
Crossref
A. Wieczorek, P. Krajewski, M. Kozioł‐Gałczyńska & J.C. Szepietowski. (2020) Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus. Journal of the European Academy of Dermatology and Venereology 34:10, pages 2368-2372.
Crossref
Yong Zhang & Mary Jeanne Kreek. (2020) Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL/6J mice. Neuropharmacology 176, pages 108244.
Crossref
Michael Soeberdt, Ana Kilic & Christoph Abels. (2020) Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages. Experimental Dermatology 29:9, pages 801-813.
Crossref
Hector Alvarado Verduzco & Shayan Shirazian. (2020) CKD-Associated Pruritus: New Insights Into Diagnosis, Pathogenesis, and Management. Kidney International Reports 5:9, pages 1387-1402.
Crossref
S. L. Huskinson, D. M. Platt, M. Brasfield, M. E. Follett, T. E. Prisinzano, B. E. Blough & K. B. Freeman. (2020) Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys. Psychopharmacology 237:7, pages 2075-2087.
Crossref
Radomir Reszke & Jacek C. Szepietowski. (2019) Can we use psychoactive drugs to treat pruritus?. Experimental Dermatology 28:12, pages 1422-1431.
Crossref
Shane W. Kaski, Allison N. White, Joshua D. Gross, Kristen R. Trexler, Kim Wix, Aubrie A. Harland, Thomas E. Prisinzano, Jeffrey Aubé, Steven G. Kinsey, Terry Kenakin, David P. Siderovski & Vincent Setola. (2019) Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine. Journal of Pharmacology and Experimental Therapeutics 371:2, pages 487-499.
Crossref
S. Stevens Negus. (2019) Core Outcome Measures in Preclinical Assessment of Candidate Analgesics. Pharmacological Reviews 71:2, pages 225-266.
Crossref
Giovanni Tangherlini, Dmitrii V. Kalinin, Dirk Schepmann, Tao Che, Nadine Mykicki, Sonja Ständer, Karin Loser & Bernhard Wünsch. (2018) Development of Novel Quinoxaline-Based κ-Opioid Receptor Agonists for the Treatment of Neuroinflammation. Journal of Medicinal Chemistry 62:2, pages 893-907.
Crossref
C. Zeidler, M. Metz, S. Steinke & S. Ständer. (2018) Therapie von chronischem Pruritus – was ist neu?Treatment of chronic pruritus—what is new?. Der Hautarzt 69:8, pages 641-646.
Crossref
Katie A. Edwards, Joshua J. Havelin, Mary I. Mcintosh, Haley A. Ciccone, Kathlene Pangilinan, Ian Imbert, Tally M. Largent-Milnes, Tamara King, Todd W. Vanderah & John M. Streicher. (2018) A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain. The Journal of Pain 19:6, pages 612-625.
Crossref
Alina Shevchenko, Rodrigo Valdes-Rodriguez & Gil Yosipovitch. (2018) Causes, pathophysiology, and treatment of pruritus in the mature patient. Clinics in Dermatology 36:2, pages 140-151.
Crossref
Tomáš Pluskal & Jing-Ke Weng. (2018) Natural product modulators of human sensations and mood: molecular mechanisms and therapeutic potential. Chemical Society Reviews 47:5, pages 1592-1637.
Crossref
Matthew L. Lazenka, Megan J. Moerke, E. Andrew Townsend, Kevin B. Freeman, F. Ivy Carroll & S. Stevens Negus. (2017) Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats. Psychopharmacology 235:1, pages 203-213.
Crossref
Tsugunobu Andoh, Takahito Maki, Sikai Li & Daisuke Uta. (2017) β2-Microglobulin elicits itch-related responses in mice through the direct activation of primary afferent neurons expressing transient receptor potential vanilloid 1. European Journal of Pharmacology 810, pages 134-140.
Crossref
E. Andrew Townsend, Jennifer E. Naylor, S. Stevens Negus, Shelley R. Edwards, Hina N. Qureshi, Hunter W. McLendon, Christopher R. McCurdy, Coco N. Kapanda, Jussara M. do Carmo, Fernanda S. da Silva, John E. Hall, Kenneth J. Sufka & Kevin B. Freeman. (2017) Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. Psychopharmacology 234:17, pages 2597-2605.
Crossref
Laura M. Bohn & Jeffrey Aubé. (2017) Seeking (and Finding) Biased Ligands of the Kappa Opioid Receptor. ACS Medicinal Chemistry Letters 8:7, pages 694-700.
Crossref
Manuel P. Pereira & Sonja Ständer. (2017) Chronic Pruritus: Current and Emerging Treatment Options. Drugs 77:9, pages 999-1007.
Crossref
Taline V. Khroyan, Andrea Cippitelli, Nicholas Toll, John A. Lawson, William Crossman, Willma E. Polgar & Lawrence Toll. (2017) In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential. Frontiers in Psychiatry 8.
Crossref
Michael Soeberdt, Peter Molenveld, Roy P. M. Storcken, Renaud Bouzanne des Mazery, Geert Jan Sterk, Reshma Autar, Marjon G. Bolster, Clemens Wagner, Sebastianus N. H. Aerts, Frank R. van Holst, Anita Wegert, Giovanni Tangherlini, Bastian Frehland, Dirk Schepmann, Dieter Metze, Tobias Lotts, Ulrich Knie, Kun-Yuan Lin, Tai-Yu Huang, Chih-Ching Lai, Sonja Ständer, Bernhard Wünsch & Christoph Abels. (2017) Design and Synthesis of Enantiomerically Pure Decahydroquinoxalines as Potent and Selective κ-Opioid Receptor Agonists with Anti-Inflammatory Activity in Vivo . Journal of Medicinal Chemistry 60:6, pages 2526-2551.
Crossref
Afton Metkowski, Rodrigo Valdes-Rodriguez & Gil Yosipovitch. 2017. Textbook of Aging Skin. Textbook of Aging Skin 485 502 .
Yunes Panahi, Simin Dashti-Khavidaki, Farahnoosh Farnood, Hamid Noshad, Mahsa Lotfi & Afshin Gharekhani. (2016) Therapeutic Effects of Omega-3 Fatty Acids on Chronic Kidney Disease-Associated Pruritus: a Literature Review. Advanced Pharmaceutical Bulletin 6:4, pages 509-514.
Crossref
Waldemar Siemens, Carola Xander, Joerg J Meerpohl, Sabine Buroh, Gerd Antes, Guido Schwarzer & Gerhild Becker. (2016) Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database of Systematic Reviews 2016:11.
Crossref
Xiulu Ruan, Stanley Martin Hall & Alan David Kaye. (2016) Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys. Journal of Pharmacological Sciences 132:1, pages 113-114.
Crossref
Paul L. Bigliardi, Yuri Dancik, Christine Neumann & Mei Bigliardi‐Qi. (2016) Opioids and skin homeostasis, regeneration and ageing – What's the evidence?. Experimental Dermatology 25:8, pages 586-591.
Crossref
Manuel P. Pereira, Andreas E. Kremer, Thomas Mettang & Sonja Ständer. (2016) Chronic Pruritus in the Absence of Skin Disease: Pathophysiology, Diagnosis and Treatment. American Journal of Clinical Dermatology 17:4, pages 337-348.
Crossref
Kristen M. Sanders, Leigh A. Nattkemper & Gil Yosipovitch. (2016) Advances in understanding itching and scratching: a new era of targeted treatments. F1000Research 5, pages 2042.
Crossref
Afton Metkowski, Rodrigo Valdes-Rodriguez & Gil Yosipovitch. 2016. Textbook of Aging Skin. Textbook of Aging Skin 1 18 .
Laurent Misery. 2016. Pruritus. Pruritus 389 392 .
Xiaoyun Cai, Huizhen Huang, Marissa S. Kuzirian, Lindsey M. Snyder, Megumi Matsushita, Michael C. Lee, Carolyn Ferguson, Gregg E. Homanics, Alison L. Barth & Sarah E. Ross. (2016) Generation of a KOR - Cre knockin mouse strain to study cells involved in kappa opioid signaling . genesis 54:1, pages 29-37.
Crossref
Afton Metkowski, Rodrigo Valdes-Rodriguez & Gil Yosipovitch. 2014. Textbook of Aging Skin. Textbook of Aging Skin 1 18 .